Koff Pharma Leadership Team
Albert D. Friesen, PhD
Co-Founder, President and CEO, Koff Pharma Inc.
Albert D. Friesen holds a Ph.D. in protein chemistry from the University of Manitoba. He has been instrumental in the founding and development of several health industry companies, including ABI Biotechnology (now Apotex Fermentation), Canada's first profitable biotech company, and the Winnipeg Rh Institute, where he led the development of Canada's first biotech product, WinRho. Dr. Friesen has also played a key role in a number of regional and national organizations, including founder and first Board of Director Chair of the Industrial Biotechnology Association of Canada (now BIOTECanada). He is President and founder of Genesys Venture Inc. (GVI), which provides the expertise for launching and managing emerging health and biotechnology ventures, including, Genesys Pharma Inc., Mantex (merged into Myogen), Miraculins, DiaMedica, Medicure and Marsala Biotech Inc.. He serves as CEO and Chair of Medicure Inc..
Marc Labelle, PhD
Co-Founder, Chief Scientific Officer, Koff Pharma Inc.
"It is with great sadness that we announce the passing of our co-founder Marc Labelle. He died peacefully after a courageous battle against a neuroendocrine tumor of the pancreas on January 1st, 2019”.
Marc Labelle obtained his Ph.D. from Université de Montréal with Professor Denis Gravel and went on to study enzyme mechanism and kinetics with Professor Ronald Breslow at Columbia University. He then joined Merck Frosst in Montréal where he was the chemistry and team leader for the discovery of asthma drug SINGULAIR™ and high density lipoprotein raising drug CORDAPTIVE™. In 2000, Dr. Labelle was hired by Tularik as Director of chemistry and led a group of chemists on a wide variety of projects. In 2004, he moved on to ImClone Systems to help build its small molecule franchise. Subsequently, he joined Lundbeck, as Vice President of chemistry. Dr. Labelle is currently a consultant with clients in the US, Canada and Europe. He was a co-founder of the Institute for Rare and Neglected Diseases Drug Discovery and is an associate professor of chemistry at Sherbrooke University. His accomplishments, which include over 50 peer-reviewed publications and 35 patent families, have been recognized by international awards including the Galien Prize and the ACS Heroes of Chemistry.